Highly sensitive detection of unintended CRISPR gene editing effects using Tracking-seq2

Tracking-seq2 demonstrates enhanced sensitivity in profiling off-target sites of gene editing technologies.

• The technology integrates specific exonuclease treatment and inhibitors targeting non-homologous end joining to improve detection.
• It is applicable to primary human cell types, including T cells and CD34+ hematopoietic stem and progenitor cells.
• Distinct off-target activity is observed across individuals due to genomic variations.
• Personalized safety assessments may be necessary for clinical applications of genome editing.
• Tracking-seq2's sensitivity is comparable to or exceeds that of existing methods.

Simplified